Companies
Wildtype
the San Francisco company whose cell-cultivated coho salmon received an FDA "no questions" letter in 2024, making it the first cultivated seafood cleared for US sale and the third cultivated protein after Upside Foods and Good Meat, with the product debuted on US restaurant menus.
- Country
- United States
FDA
ISO 22000
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | More than $123.5 million raised in total funding | biobase.whitefordresearch.com · agfundernews.com · parsers.vc · trial.medpath.com · yespress.io |
| Capacity | Capable of producing 200,000 pounds of salmon per year | parsers.vc |
| Regulatory approval | FDA 'no questions' letter received for cell-cultivated coho salmon on May 28, 2025 | biobase.whitefordresearch.com · agfundernews.com · aglaw.psu.edu · trial.medpath.com |
| Production site | Demonstration-scale 'Fishery' pilot plant in San Francisco, California | biobase.whitefordresearch.com |
| Headcount | Estimated between 51 and 200 employees medium confidence | simplify.jobs · sfexaminer.com · yespress.io |
Independent sources: agfundernews.com · aglaw.psu.edu · biobase.whitefordresearch.com · parsers.vc · sfexaminer.com · simplify.jobs · trial.medpath.com · yespress.io
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Cultured seafood | food-alt-protein | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.